Protagonist Therapeutics, Inc.

PTGX US Health Care Biotechnology
S&P 600
$148.18
+2.08%
Delayed · cached 15 min

Fair value analysis

Reported earnings per share are negative or zero, so the earnings-based models cannot produce a value.

Financial DNA score 27 / 100

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.